Alvotech and DKSH recently announced an expansion of their strategic partnership to commercialize six new biosimilar candidates for the Asian
markets. The press release does not name the biosimilar candidates, but states that they “address[] multiple therapeutic areas.” The companies previously entered into an exclusive license partnership for Alvotech’s adalimumab biosimilar in selected Asian markets in March 2020.
According to the press release, “Alvotech has made very important strategic partnership agreements with leading regional and global industry players including: Teva in the U.S., Stada in Europe, JAMP in Canada, Yas Holding in the Middle East and Fuji Pharma in Japan” over the past twelve months.